Interview with the Innovators

Navigating Patients with Chronic Lymphocytic Leukemia: An interview with Nikki Barkett, BSN, RN, OCN, and Chelsea Passwater, DNP, RN, AGCNS-BC, OCN, of the AONN+ CLL CAPE Initiative

In this Interview with the Innovator video, Melissa Simon, BSN, RN, OCN, ONN-CG, and Emily Beard, RN, BSN, OCN, CBCN, discuss common and expected side effects with ovarian function suppression as well as adverse side effects to monitor and report to a healthcare provider.

IWTI 2022

September 2022 Vol 13, No 9

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The American Cancer Society estimates over 20,000 new CLL cases and over 4000 attributed deaths in 2022.

Insights into the Prostate Cancer Imaging Landscape

Dr Steven Rowe continues his discussion of PYLARIFY^® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.

Results from the OSPREY Trial in Pre-Prostatectomy Patients

Dr Steven Rowe continues his discussion of PYLARIFY^® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.

PYLARIFY Imaging in High-Risk Prostate Cancer

Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.

Overview of the Molecular Characteristics of PYLARIFY

Dr Steven Rowe details the molecular characteristics of PYLARIFY^® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY^®.

The Importance of Accurate Staging in Prostate Cancer

By Neal D. Shore, MD

Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer

Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.

IWTI 2021

Interview with the Innovators, Prostate Cancer

Interview with the Innovators – December 2021

A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC.

Use of PYLARIFY® in Specific Patient Groups

By Neal D. Shore, MD